

Mahajan, Vinay

From: Communications, Novartis (Gen)
Sent: Thursday, January 11, 2018 11:42 AM
To: Mahajan, Vinay
Subject: Letter to associates from Vas Narasimhan: Novartis Leadership Announcement



Novartis Leadership Announcement

January 11, 2018

Dear Novartis Associates,

I am very pleased to announce that **Elizabeth (Liz) Barrett**, Global President Oncology at Pfizer, Inc., has been appointed *CEO Novartis Oncology* and a member of the Executive Committee of Novartis, effective February 1, 2018.

Liz is a highly accomplished and recognized oncology leader with a strong patient orientation and commitment to the purpose of curing cancer. As a people leader, she is aligned with the inspired and empowered culture we want to build. Liz has an impressive record of achievements in the US, Europe and globally. Throughout her career, she has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities. Her breadth and depth of pharmaceutical industry experience built on an early foundation of consumer marketing skills and perspectives positions Liz well to further develop our oncology business and strengthen our commercial excellence and launch capabilities.

In her role at Pfizer, she led a transformation in less than three years growing their oncology business from a small niche player to a top-six oncology company. Widely known as a team player, Liz has forged strong collaborations with R&D and external partners. Before joining Pfizer in 2009, she worked at Cephalon, Inc. and Johnson & Johnson. She started her career at Kraft Foods Group, Inc. in 1984, where she became an accomplished consumer marketer, and later applied these skills successfully in the pharmaceutical industry. Liz has an MBA in Marketing from the Saint Joseph's University in Philadelphia and a BSc in Business Administration from the University of Louisiana, USA. Liz is a US citizen and has lived and worked in the US and Europe. She will be based in Basel, Switzerland.

Please join me in welcoming Liz to Novartis and wishing her much success. We look forward to her joining us in our commitment to reimagine medicine by transforming cancer care.

To help me focus on my new role as CEO of Novartis starting on February 1, we have appointed **Rob Kowalski**, Head of Global Regulatory Affairs and US Head of Development, to lead *ad interim* the Global Drug Development organization. Rob is an accomplished leader at Novartis and in our industry. He has been instrumental in securing approvals for several breakthrough medicines including our revolutionary CAR-T therapy Kymriah™.

I would like to thank Rob for agreeing to lead our Global Drug Development organization *ad interim*, wishing him much success. I am confident we will have a permanent successor in place soon.

Best regards,

Vas

For internal use only and not to be shown, distributed or disseminated outside of Novartis



